Orchestra BioMed's AVIM Therapy Shows Immediate Blood Pressure Reduction in MODERATO II Trial
Event summary
- AVIM Therapy demonstrated an immediate average reduction of 13.2 mmHg in office systolic blood pressure (oSBP) upon activation in the MODERATO II trial.
- 97% of patients experienced a >5 mmHg reduction in oSBP prior to randomization.
- At 6 months, mean ambulatory systolic blood pressure (aSBP) was 125.2 mmHg, with 89% of patients achieving aSBP <140 mmHg.
- BACKBEAT Global Pivotal Trial is actively enrolling as part of a strategic collaboration with Medtronic.
The big picture
Orchestra BioMed's AVIM Therapy is positioning itself as a differentiated solution for hypertensive heart disease, leveraging strategic partnerships to navigate the multi-billion-dollar global market for blood pressure management. The immediate and sustained reductions in blood pressure observed in MODERATO II highlight its potential to address unmet needs in high-risk patient populations.
What we're watching
- Clinical Validation
- How the sustained blood pressure reduction data from MODERATO II will impact the ongoing BACKBEAT trial and regulatory approval prospects.
- Partnership Dynamics
- Whether Orchestra BioMed's collaboration with Medtronic can accelerate commercialization of AVIM Therapy in the competitive hypertension treatment market.
- Market Adoption
- The pace at which AVIM Therapy could gain traction among pacemaker-indicated patients with uncontrolled hypertension, given its non-pharmacological approach.